Amplia Therapeutics Ltd (ASX: ATX) Share Price and News
Price
Movement
52 Week Range
-
1 Year Return
(20 mins delayed)
() Chart and Price Data
Share Price
Previous Close
Volume
Day Change
Open
Monthly Average Volume
52 Week Range
-
Days Range
-
Turnover
Fundamental Company Figures
Data provided by Morningstar.
Market Cap
$29.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Shares Outstanding
107.86 million
Earnings per share
-0.031
Dividend per share
N/A
Year To Date Return
16.67%
Earnings Yield
N/A
Franking
N/A
Amplia Therapeutics Ltd (ASX: ATX) Latest News
Here’s why the Amplia (ASX:ATX) share price is up 9% today
Aaron Teboneras | February 17, 2021 1:19pm
Amplia Therapeutics share price up 16% in 2 days as former Macquarie CEO takes substantial stake
Chris Chitty | July 15, 2020 2:04pm
US congressman resigns over ASX insider trading penny stock scandal
Tom Richardson | October 1, 2019 12:57pm
ASX Watergate Arrest: The alleged insider trading at Innate Immunotherapeutics Ltd (ASX:IIL)
Sean O'Neill | August 9, 2018 1:10pm
Cann Group Ltd is one of 64 new shares added to the All Ordinaries this quarter
James Mickleboro | March 9, 2018 10:05am
Were these the 3 worst shares on the ASX in 2017?
James Mickleboro | December 29, 2017 2:40pm
These are the 5 biggest losers on the All Ordinaries in the last 12 months
James Mickleboro | August 17, 2017 1:31pm
One crucial thing to consider before investing in risky biotech shares
Sean O'Neill | August 10, 2017 3:53pm
Recent Stock Announcements
Price Sensitive OnlyAn announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Show All
| Date | Heading | An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. | Time | Pages | File Size |
|---|---|---|---|---|---|
About Amplia Therapeutics Ltd (ASX: ATX)
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
Share Price History
Data provided by Morningstar.| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 26 Feb 2021 | $0.28 | $-0.01 | -3.57% | 222,273 | $0.28 | $0.28 | $0.26 |
| 25 Feb 2021 | $0.28 | $0.01 | 3.70% | 57,734 | $0.27 | $0.28 | $0.27 |
| 24 Feb 2021 | $0.27 | $-0.01 | -3.64% | 1,789 | $0.27 | $0.27 | $0.27 |
| 23 Feb 2021 | $0.28 | $0.00 | 0.00% | 39,962 | $0.28 | $0.28 | $0.28 |
| 22 Feb 2021 | $0.28 | $-0.01 | -3.51% | 127,876 | $0.29 | $0.29 | $0.27 |
| 19 Feb 2021 | $0.29 | $0.00 | 0.00% | 56,590 | $0.29 | $0.29 | $0.28 |
| 17 Feb 2021 | $0.29 | $0.02 | 7.41% | 371,454 | $0.29 | $0.30 | $0.29 |
| 16 Feb 2021 | $0.27 | $-0.01 | -3.57% | 77,472 | $0.29 | $0.29 | $0.27 |
| 15 Feb 2021 | $0.28 | $0.01 | 3.70% | 52,000 | $0.28 | $0.29 | $0.28 |
| 12 Feb 2021 | $0.27 | $-0.01 | -3.64% | 18,687 | $0.27 | $0.27 | $0.27 |
| 11 Feb 2021 | $0.28 | $0.01 | 3.70% | 150,721 | $0.27 | $0.29 | $0.27 |
| 10 Feb 2021 | $0.27 | $0.00 | 0.00% | 48,233 | $0.27 | $0.27 | $0.27 |
| 09 Feb 2021 | $0.27 | $-0.01 | -3.64% | 78,673 | $0.28 | $0.28 | $0.27 |
| 08 Feb 2021 | $0.28 | $0.01 | 3.70% | 109,568 | $0.27 | $0.28 | $0.26 |
| 05 Feb 2021 | $0.27 | $0.01 | 3.85% | 178,098 | $0.27 | $0.27 | $0.26 |
| 04 Feb 2021 | $0.26 | $-0.01 | -3.70% | 88,785 | $0.26 | $0.27 | $0.26 |
| 03 Feb 2021 | $0.27 | $0.01 | 3.85% | 156,745 | $0.26 | $0.27 | $0.26 |
| 02 Feb 2021 | $0.26 | $0.00 | 0.00% | 67,398 | $0.26 | $0.26 | $0.26 |
| 01 Feb 2021 | $0.26 | $-0.01 | -3.77% | 187,639 | $0.27 | $0.27 | $0.26 |
| 29 Jan 2021 | $0.27 | $-0.01 | -3.70% | 122,313 | $0.27 | $0.28 | $0.27 |
| 28 Jan 2021 | $0.27 | $-0.03 | -10.17% | 391,247 | $0.29 | $0.29 | $0.27 |
Director Transactions
Data provided by Morningstar.Directors & Management
Data provided by Morningstar.Top Share Holders
Data provided by Morningstar.| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 17,398,080 | 20.15% |
| Bond Street Custodians Limited <LAM1 - D08047 A/C> | 7,500,000 | 8.69% |
| Citicorp Nominees Pty Limited | 7,397,724 | 8.57% |
| CTXT Pty Ltd | 4,514,468 | 5.23% |
| Elk River Holdings Pty Ltd | 2,942,142 | 3.41% |
| Christopher John Burns | 2,275,237 | 2.64% |
| 34th Avenue Pty Ltd <Devlin Family A/C> | 2,215,237 | 2.57% |
| Warwick Tong | 1,941,428 | 2.25% |
| Mark Sullivan <AEMS Consulting A/C> | 1,661,428 | 1.92% |
| Merrill Lynch (Australia) Nominees Pty Limited | 1,534,712 | 1.78% |
| Cancer Research Technology Limited | 1,360,524 | 1.58% |
| Cofactor LLC | 1,000,000 | 1.16% |
| HWH Power Pty Ltd <HWH Super Fund A/C> | 950,000 | 1.10% |
| Margaret Frame | 923,016 | 1.07% |
| Calama Holdings Pty Ltd <Mambat Super Fund A/C> | 875,000 | 1.01% |
| Symington Pty Ltd | 710,000 | 0.82% |
| Mr Andrew Podolak | 610,000 | 0.71% |
| Yelwac Pty Ltd <The Cawley Superfund No2 A/C> | 600,000 | 0.69% |
| Mr Li Sun | 580,000 | 0.67% |
| Mrs Patricia Watkins + Mr John Phibbs + Mr Graeme Halse | 566,625 | 0.66% |